KF 31327

Drug Profile

KF 31327

Latest Information Update: 21 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Hakko Kirin
  • Class Quinazolines; Small molecules; Thiones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
  • 01 Jul 2004 KF 31327 is available for licensing (http://www.kyowa.co.jp/eng/)
  • 04 Feb 2003 A preclinical study has been added to the Mens Health pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top